Characteristics of participants with covid-19 and matched control participants without covid-19 and those with a first venous thromboembolic or bleeding event during days 1-30 after covid-19* or index date. Values are numbers (percentages) unless stated otherwise
| Cohorts | Deep vein thrombosis | Pulmonary embolism | Bleeding | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases (n=1 057 174) | Controls (n=4 076 342) | Cases (n=401) | Controls (n=267) | Cases (n=1761) | Controls (n=171) | Cases (n=1002) | Controls (n=1292) | ||||
| Mean (SD) age (years) | 40.2 (19) | 40.2 (19.1) | 59.3 (15.5) | 55.8 (17.8) | 62.5 (15.3) | 62.2 (18.7) | 62.7 (18.4) | 54.3 (19.9) | |||
| Sex: | |||||||||||
| Men | 517 434 (48.9) | 2 000 973 (49.1) | 244 (60.8) | 140 (52.4) | 1170 (66.4) | 83 (48.5) | 546 (54.5) | 508 (39.3) | |||
| Women | 539 740 (51.055) | 2 075 369 (50.913) | 157 (39.2) | 127 (47.6) | 591 (33.6) | 88 (51.5) | 456 (45.5) | 784 (60.7) | |||
| Died | 19 073 (1.8) | 13 675 (0.3) | 46 (11.5) | 21 (7.9) | 281 (16) | 22 (12.9) | 195 (19.5) | 83 (6.4) | |||
| Disease severity: | |||||||||||
| Uninfected | - | 4 076 342 (100) | - | 267 (100) | - | 171 (100) | - | 1292 (100) | |||
| Mild | 999 113 (94.5) | - | 155 (38.7) | - | 239 (13.6) | - | 349 (34.8) | - | |||
| Hospital admission | 50 279 (4.8) | - | 163 (40.6) | - | 1037 (58.9) | - | 467 (46.6) | - | |||
| Intensive care unit admission | 7782 (0.7) | - | 83 (20.7) | - | 485 (27.5) | - | 186 (18.6) | - | |||
| Mean (SD) wCCI score | 0.81 (1.9) | 0.73 (1.8) | 1.57 (2.5) | 1.90 (2.4) | 1.48 (2.3) | 2.29 (2.9) | 1.98 (2.68) | 1.54 (2.4) | |||
| Previous venous thromboembolism† | 19 988 (1.9) | 63 895 (1.6) | - | - | - | - | - | - | |||
| Previous bleeding | 61 150 (5.8) | 200 672 (4.9) | - | - | - | - | - | - | |||
wCCI=weighted Charlson comorbidity index.
* Earliest date from date of disease onset, sample date, diagnosis date, or date of report to the communicable disease surveillance system SmiNet (Public Health Agency of Sweden).
† Event (deep vein thrombosis, pulmonary embolism, pregnancy related thrombosis, or bleeding) occurred between 1987 and day 0 (date of covid-19 or index date) for participants with covid-19 and between 1997 and day 0 for control participants.